Karin Rosen
Chief Tech/Sci/R&D Officer bij HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Actieve functies van Karin Rosen
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 02-11-2020 | - |
| DIAMYD MEDICAL AB | Director/Board Member | 10-03-2023 | - |
Loopbaan van Karin Rosen
Eerdere bekende functies van Karin Rosen
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| GSK PLC | Corporate Officer/Principal | 01-11-2018 | 01-11-2020 |
Opleiding van Karin Rosen
| University of Lund | Doctorate Degree |
Statistieken
Internationaal
| Zweden | 3 |
| Ierland | 2 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GSK PLC | Health Technology |
| DIAMYD MEDICAL AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Beurs
- Insiders
- Karin Rosen
- Ervaring
